1190 related articles for article (PubMed ID: 9751087)
1. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Maini RN; Breedveld FC; Kalden JR; Smolen JS; Davis D; Macfarlane JD; Antoni C; Leeb B; Elliott MJ; Woody JN; Schaible TF; Feldmann M
Arthritis Rheum; 1998 Sep; 41(9):1552-63. PubMed ID: 9751087
[TBL] [Abstract][Full Text] [Related]
2. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis.
Abe T; Takeuchi T; Miyasaka N; Hashimoto H; Kondo H; Ichikawa Y; Nagaya I
J Rheumatol; 2006 Jan; 33(1):37-44. PubMed ID: 16395748
[TBL] [Abstract][Full Text] [Related]
5. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial.
Fleischmann RM; Cohen SB; Moreland LW; Schiff M; Mease PJ; Smith DB; Keenan G; Kremer JM;
Curr Med Res Opin; 2005 Aug; 21(8):1181-90. PubMed ID: 16083527
[TBL] [Abstract][Full Text] [Related]
6. Treatment with infliximab plus methotrexate improves anemia in patients with rheumatoid arthritis independent of improvement in other clinical outcome measures-a pooled analysis from three large, multicenter, double-blind, randomized clinical trials.
Doyle MK; Rahman MU; Han C; Han J; Giles J; Bingham CO; Bathon J
Semin Arthritis Rheum; 2009 Oct; 39(2):123-31. PubMed ID: 18823645
[TBL] [Abstract][Full Text] [Related]
7. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial.
Cohen S; Hurd E; Cush J; Schiff M; Weinblatt ME; Moreland LW; Kremer J; Bear MB; Rich WJ; McCabe D
Arthritis Rheum; 2002 Mar; 46(3):614-24. PubMed ID: 11920396
[TBL] [Abstract][Full Text] [Related]
8. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Quinn MA; Conaghan PG; O'Connor PJ; Karim Z; Greenstein A; Brown A; Brown C; Fraser A; Jarret S; Emery P
Arthritis Rheum; 2005 Jan; 52(1):27-35. PubMed ID: 15641102
[TBL] [Abstract][Full Text] [Related]
9. Treatment of early seropositive rheumatoid arthritis: doxycycline plus methotrexate versus methotrexate alone.
O'Dell JR; Elliott JR; Mallek JA; Mikuls TR; Weaver CA; Glickstein S; Blakely KM; Hausch R; Leff RD
Arthritis Rheum; 2006 Feb; 54(2):621-7. PubMed ID: 16447240
[TBL] [Abstract][Full Text] [Related]
10. Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I/II randomized, blinded, placebo-controlled, dose-ranging study.
Genovese MC; Kaine JL; Lowenstein MB; Del Giudice J; Baldassare A; Schechtman J; Fudman E; Kohen M; Gujrathi S; Trapp RG; Sweiss NJ; Spaniolo G; Dummer W;
Arthritis Rheum; 2008 Sep; 58(9):2652-61. PubMed ID: 18759293
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study.
Weinblatt ME; Schiff MH; Ruderman EM; Bingham CO; Li J; Louie J; Furst DE
Arthritis Rheum; 2008 Jul; 58(7):1921-30. PubMed ID: 18576334
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study.
Gerloni V; Pontikaki I; Gattinara M; Desiati F; Lupi E; Lurati A; Salmaso A; Fantini F
Arthritis Rheum; 2005 Feb; 52(2):548-53. PubMed ID: 15693004
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial.
Emery P; Fleischmann R; Filipowicz-Sosnowska A; Schechtman J; Szczepanski L; Kavanaugh A; Racewicz AJ; van Vollenhoven RF; Li NF; Agarwal S; Hessey EW; Shaw TM;
Arthritis Rheum; 2006 May; 54(5):1390-400. PubMed ID: 16649186
[TBL] [Abstract][Full Text] [Related]
14. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study.
Kremer J; Ritchlin C; Mendelsohn A; Baker D; Kim L; Xu Z; Han J; Taylor P
Arthritis Rheum; 2010 Apr; 62(4):917-28. PubMed ID: 20131276
[TBL] [Abstract][Full Text] [Related]
15. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis.
Visvanathan S; Wagner C; Smolen J; St Clair EW; Hegedus R; Baker D; Keenan G
Arthritis Rheum; 2006 Sep; 54(9):2840-4. PubMed ID: 16948115
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the safety of rituximab in combination with a tumor necrosis factor inhibitor and methotrexate in patients with active rheumatoid arthritis: results from a randomized controlled trial.
Greenwald MW; Shergy WJ; Kaine JL; Sweetser MT; Gilder K; Linnik MD
Arthritis Rheum; 2011 Mar; 63(3):622-32. PubMed ID: 21360491
[TBL] [Abstract][Full Text] [Related]
17. A 48-week, randomized, double-blind, double-observer, placebo-controlled multicenter trial of combination methotrexate and intramuscular gold therapy in rheumatoid arthritis: results of the METGO study.
Lehman AJ; Esdaile JM; Klinkhoff AV; Grant E; Fitzgerald A; Canvin J;
Arthritis Rheum; 2005 May; 52(5):1360-70. PubMed ID: 15880810
[TBL] [Abstract][Full Text] [Related]
18. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
[TBL] [Abstract][Full Text] [Related]
19. A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.
Ruperto N; Lovell DJ; Cuttica R; Wilkinson N; Woo P; Espada G; Wouters C; Silverman ED; Balogh Z; Henrickson M; Apaz MT; Baildam E; Fasth A; Gerloni V; Lahdenne P; Prieur AM; Ravelli A; Saurenmann RK; Gamir ML; Wulffraat N; Marodi L; Petty RE; Joos R; Zulian F; McCurdy D; Myones BL; Nagy K; Reuman P; Szer I; Travers S; Beutler A; Keenan G; Clark J; Visvanathan S; Fasanmade A; Raychaudhuri A; Mendelsohn A; Martini A; Giannini EH; ;
Arthritis Rheum; 2007 Sep; 56(9):3096-106. PubMed ID: 17763439
[TBL] [Abstract][Full Text] [Related]
20. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis.
Shergy WJ; Isern RA; Cooley DA; Harshbarger JL; Huffstutter JE; Hughes GM; Spencer-Smith EA; Goldman AL; Roth SH; Toder JS; Warner D; Quinn A; Keenan GF; Schaible TF;
J Rheumatol; 2002 Apr; 29(4):667-77. PubMed ID: 11950005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]